Earnings Call Summary | NANALYSIS SCIENTIFIC CORP(NSCIF.US) Q4 2023 Earnings Conference
Earnings Call Summary | NANALYSIS SCIENTIFIC CORP(NSCIF.US) Q4 2023 Earnings Conference
The following is a summary of the Nanalysis Scientific Corp. (NSCIF) Q4 2023 Earnings Call Transcript:
以下是Nanalysis Scientific Corp.（NSCIF）2023年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Nanalysis reported Q4 2023 revenue of $9.8 million, up 36% compared to Q4 2022. This included $5.5 million from product sales and $4.4 million from service revenue.
The company incurred an EBITDA loss of $774,000, a marked improvement from the $2.5 million loss in 2022.
Full-year consolidated revenue for 2023 was $28 million, up 15% compared to the prior year.
Gross margin percentage for product sales was 41% for the 12-month period, lower than 49% in the previous year due to market and supply chain issues. However, this figure is expected to improve due to cost-cutting initiatives and market improvements.
Nanalysis報告稱，2023年第四季度收入爲980萬美元，與2022年第四季度相比增長36％。這包括來自產品銷售的550萬美元和來自服務收入的440萬美元。
該公司的息稅折舊攤銷前利潤虧損爲77.4萬美元，較2022年的250萬美元虧損有了顯著改善。
2023年全年合併收入爲2,800萬美元，與上年相比增長15％。
由於市場和供應鏈問題，產品銷售的毛利率在12個月內爲41％，低於上年的49％。但是，由於削減成本的舉措和市場的改善，這一數字預計將有所改善。
Business Progress:
業務進展：
Nanalysis expects high costs related to the Airport Security Project to decrease as the project becomes fully operational in 2024.
High expectations are held for the high-field NMR product line, and progress is being made on a large custom MRI installation.
Significant cost-cutting measures such as layoffs, particularly in Q2, have resulted in improved gross margins in Q4 of 2023.
The company expects full-scale revenue and continued growth in Security Services in 2024.
Nanalysis預計，隨着機場安全項目於2024年全面投入運營，與該項目相關的高成本將降低。
人們對高場核磁共振產品線寄予厚望，大型定製核磁共振裝置正在取得進展。
裁員等重大成本削減措施，尤其是在第二季度，使2023年第四季度的毛利率有所提高。
該公司預計，2024年安全服務將實現全面收入和持續增長。
More details: NANALYSIS SCIENTIFIC CORP IR
更多詳情： NANALYSIS 科學公司
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。